News
IDYA
36.68
-0.16%
-0.06
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Spyre Therapeutics (SYRE) and IDEAYA Biosciences (IDYA)
TipRanks · 5h ago
Weekly Report: what happened at IDYA last week (0803-0807)?
Weekly Report · 1d ago
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Q2 Losses And IDE892 Trial Expansion
Simply Wall St · 2d ago
LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
TipRanks · 3d ago
Ideaya Biosciences price target lowered to $42 from $45 at Citizens
TipRanks · 4d ago
IDEAYA Biosciences (IDYA) Stock Could Be Fully Valued After Trial Progress
Simply Wall St · 5d ago
IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital
TipRanks · 5d ago
IDEAYA Biosciences Is Maintained at Buy by Truist Securities
Dow Jones · 5d ago
IDEAYA Biosciences Price Target Cut to $59.00/Share From $63.00 by Truist Securities
Dow Jones · 5d ago
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59
Benzinga · 5d ago
Ideaya Biosciences price target lowered to $59 from $63 at Truist
TipRanks · 6d ago
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60
Benzinga · 6d ago
IDEAYA Biosciences (IDYA) Stock Faces Loss Pressure Despite Revenue Traction
Simply Wall St · 6d ago
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and TransMedics Group (TMDX)
TipRanks · 6d ago
Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05)
TipRanks · 08/04 11:36
IDEAYA Biosciences GAAP EPS of -$1.22 misses by $0.14, revenue of $8.86M beats by $1.41M
Seeking Alpha · 08/04 10:13
IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate
Benzinga · 08/04 10:11
*IDEAYA Biosciences 2Q Research and Development Expenses $108.7M >IDYA
Dow Jones · 08/04 10:04
*IDEAYA Biosciences 2Q Rev $8.86M >IDYA
Dow Jones · 08/04 10:03
*IDEAYA Biosciences 2Q Loss/Shr $1.22 >IDYA
Dow Jones · 08/04 10:03
More
Webull provides a variety of real-time IDYA stock news. You can receive the latest news about Ideaya Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.